🔗 Share this article

Given that America proceeds with unprecedented changes to its vaccination guidelines, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning coronavirus vaccinations throughout the global health crisis and has focused upon alleged fatalities following Covid immunization in her recent tenure at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities planned to announce radical changes to the childhood vaccination calendar earlier this month, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with a large portion of the world with no evidence for improved outcomes. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth individual to run the division this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the drug and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – usually the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no apparent background in medication creation, regulation or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a major agency. She is not an expert in industry regulation.”

Former directors of the center would “understand laws and regulations and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who ran the center have had.”

This division has an vast workload at the agency, she stated.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and each of these have to be managed,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative component to the job, which supervises in excess of 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” Woodcock added.

Official Statement and Disputed Programs

In response to concerns about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among agency officials on vaccines, a representative responded that the “concerns stem from incorrect presumptions”.

“Her resume is consistent with the responsibilities of her job,” the spokesperson explained, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s new expedited review system, a disputed expedited drug-approval program that reportedly worried her predecessors. “By what process are these medications being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed oversight of all drugs, aside from immunizations.”

Public Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, history, Howard have noted. She published a research paper using unconfirmed volunteer-provided data to determine the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the current administration featured altering regulations for recently developed shots and discontinuing “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested barring young men from getting COVID-19 vaccines.

“She is an thorough true believer who begins with her beliefs and tailors the evidence to retrofit the evidence in a very deceptive, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|